For questions regarding claiming CME Credit, please refer to our FAQ section.



 

Enhancing ACS Outcomes

Program Overview:

Antiplatelet therapy is a complex and integral part of care for patients who present with ACS or undergo percutaneous coronary intervention (PCI) and individualization of antiplatelet therapy is essential to delivering guideline-directed care. Selecting antiplatelet therapy continues to be one of the single greatest challenges in interventional cardiology practice, and is the topic of intense debate in current literature. Although truly individualized management is not yet possible, many inferences can be made based on the existing body of evidence. In order to provide evidence-based care for patients and minimize the risk of ischemic complications, interventional cardiologists must inspect many different perspectives regarding what factors to consider in antiplatelet selection. This activity will provide interventionalists with the necessary framework for tailoring antiplatelet therapy in patients at risk for acute coronary syndromes.

Click Hereto access this CME Program

 

Release Date:
January 31, 2014

 

Expiration Date:
July 31, 2014 

  Estimated Time:
1 hour

 

 

EUROMAX and SAFE PCI

Program Overview:

The SAFE-PCI trial is the first all-female cardiovascular clinical trial examining whether radial access reduces bleeding complications for either catheterization or PCI. SAFE-PCI enrolled over 1700 women from 60 US sites.
The EURO-MAX study examines the value of giving bivalirudin en route to the hospital in a randomized trial with over 2,000 STEMI patients receiving contemporary care from 60 European centers.
In this webcast, the faculty panel will discuss the results of these trials and the implications for clinical practice.

Click Hereto access this CME Program

 

Release Date:
December 13, 2013

 

Expiration Date:
June 13, 2014 

  Estimated Time:
1 hour

 

 

Post-AHA 2013 CME Webcast

Program Overview:

The ERASE trial (Endovascular Revascularization and Supervised Exercise trial) examined endovascular revascularization combined with structured exercise compared to structured exercise alone in patients with stable intermittent claudication. Over 200 patients randomized between the two arms were followed for year comparing changes from baseline in walking distance, quality of life measures, ABI and amputation/reintervention.

The CORAL trial (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) from the National Heart Lung Blood Institute studies whether optimal medical therapy plus renal artery stenting was superior to optimal medical therapy alone in patients with stage 3 or higher chronic kidney disease or severe hypertension. Over 800 patients were followed for five years for occurrence of renal or cardiac events.

 Click Hereto access this CME Program 

 

Release Date:
December 19, 2013

 

Expiration Date:
June 19, 2014 

  Estimated Time:
1 hour

 

ARCTIC INTERRUPTION and OPTIMZE

 

Program Overview:

Current practices for dual antiplatelet therapy (DAPT) and drug-eluting stents (DES) are being questioned given the improved safety with second generation DES. Stent thrombosis rates are less than 1% at one year for second generation DES. In the recent report from the real world  PARIS registry, DAPT past one year did not confer additional protection against stent thrombosis in higher risk patients (prior MI, prior CABG, diabetes). These findings are attributed in part to second-generation DES. The majority of stent thrombosis and MACE (74%) occur while patients are on DAPT. Two trials with results at TCT 2013, OPTIMIZE and ARCTIC, further investigated DAPT duration with second generation DES.

Click Hereto access this CME Program

 

Release Date:
December 2, 2013

 

Expiration Date:
June 2, 2014 

  Estimated Time:
1 hour

 

Updates in TAVR 200x100

 

Program Overview:

Successful TAVR procedures blend appropriate patient selection with best practices in procedure planning. In US practices, the overall in-hospital mortality rate is 5.5%, the stroke rate is 2.0%, and device implantation success is 92% since TAVR became commercially available in 2011.¹ The PARTNER trials provided valuable insights into frailty for patient selection and the rates of paravalvular leak. The newly completed CoreValve Extreme risk trial offers further valuable insights in patient selection and best procedure practices. Valve sizing with 3-D instead of 2-D imaging has been recognized in the past year as impacting paravalvular leak rates. Similarly, access sites remain an issue of growth and controversy for TAVR.

Click Hereto access this CME Program

 

Release Date:
November 22, 2013

 

Expiration Date:
May 22, 2014 

  Estimated Time:
1 hour

 

2013-11-19-Efficient and Affordable TAVR Program

 

Program Overview:

With the advent of transcatheter aortic valve replacement (TAVR), patients can benefit from a less invasive alternative to conventional surgery. However, the catheter-based procedure is complex and requires operators to undergo intensive training to ensure safety and efficacy. This webcast will address the critical need for education programs to guide practitioners as they incorporate TAVR into practice. It will provide information on patient evaluation and selection, cost-effectiveness, and postprocedural management.

Click Hereto access this CME Program

 

Release Date:
November 19, 2013

 

Expiration Date:
May 19, 2014 

  Estimated Time:
1 hour
 

  hyperchol cme 200x100

Program Overview:

Join an international faculty of 11 leading FH specialists, cardiologists and lipidologists as they participate in a forum called the iQ&A interactive Medical Intelligence Zone for Familial Hypercholesterolemia. This global panel will analyze, answer and discuss 70+ FAQs addressing clinical dilemmas and therapeutic advances for patients with familial hypercholesterolemia

Click Hereto access this CME Program

 

Release Date:
April 30, 2012

  Expiration Date:
April 30, 2014
  Estimated Time:
4 hours